Epinastine (epinastine HCl)

No dosing information is available for this tab.

For topical ophthalmic use only. Not for injection or oral use.

No formal drug interaction studies have been performed.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

Known hypersensitivity to epinastine or any ingredient in the formulation.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

• No disease contraindications

Adverse ocular effects reported in approximately 1-10% of patients include ocular burning, folliculosis, hyperemia, and pruritus.

The most frequently reported adverse nonocular effect is infection (e.g., cold symptoms, upper respiratory infections), which occurred in approximately 10% of patients. Other adverse nonocular effects reported in approximately 1-3% of patients include headache, rhinitis, sinusitis, increased cough, and pharyngitis.

Some events may be related to the underlying ocular disease rather than epinastine.

More Frequent

• Follicular conjunctivitis

More Frequent

• Cold symptoms
• Rhinorrhea
• Sore throat
• Upper respiratory infection

Less Frequent

• Cough
• Headache disorder
• Ocular irritation
• Ocular redness
• Pharyngitis
• Pruritus of skin
• Rhinitis
• Sinusitis

No enhanced messaging available.

Safety and efficacy not established in children younger than 3 years of age.

Category C. (See Users Guide.)

Epinastine is distributed into milk in rats. It is not known whether the drug is distributed into human milk; therefore, caution should be exercised when ocular epinastine is administered to a nursing woman.

No overall differences in safety and efficacy relative to younger patients.